Home Cart Sign in  
Chemical Structure| 1207293-36-4 Chemical Structure| 1207293-36-4

Structure of BI-847325
CAS No.: 1207293-36-4

Chemical Structure| 1207293-36-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BI-847325 is a selective and orally bioavailable dual MEK/Aurora kinase inhibitor with IC50 of 3 nM (Xenopus laevis Aurora B), 25 nM (human Aurora A), 15 nM (human Aurora C), 25 nM (human MEK1), and 4 nM (human MEK2) respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BI-847325

CAS No. :1207293-36-4
Formula : C29H28N4O2
M.W : 464.56
SMILES Code : O=C(NCC)C#CC1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(CN(C)C)C=C3)/C4=CC=CC=C4
MDL No. :MFCD28978743
InChI Key :OCUQMWSIGPQEMX-UHFFFAOYSA-N
Pubchem ID :135567102

Safety of BI-847325

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of BI-847325

epigenetics
DNA
MAPK

Isoform Comparison

Biological Activity

Target
  • Aurora A

    Aurora A (Human), IC50:25 nM

  • Aurora B

    Aurora B (Xenopus laevis), IC50:3 nM

  • Aurora C

    Aurora C (Human), IC50:15 nM

  • MEK2

    MEK2, IC50:4 nM

  • MEK1

    MEK1, IC50:25 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
WM793R 300nM–3µM 48 hours BI-847325 induced cell death in 3D organotypic cell culture models. PMC4458462
WM793 30–300 nM 4 weeks Inhibition of Smad2 and Smad3 linker region phosphorylation PMC4458462
1205Lu 1 nM to 30 µM 72 hours Inhibition of Smad2 and Smad3 linker region phosphorylation PMC4458462
Melanoma cells 0.004-30 μmol/L 4 days SR9011 induces apoptosis in melanoma cells PMC10599287
1205LuR 10nM – 1µM 48 hours BI-847325 induced significant apoptosis in BRAF-mutant and vemurafenib-resistant melanoma cell lines. PMC4458462
Mammary cancer cells 0.004-30 μmol/L 4 days Evaluate the antiproliferative activity of BI-847325 on mammary cancer cells, showing high sensitivity PMC10599287
Colorectal cancer cells 0.004-30 μmol/L 4 days Dioscin inhibited Skp2 expression, reduced pAkt and HK2 expression, and suppressed glycolysis PMC10599287
Bladder cancer cells 0.004-30 μmol/L 4 days Evaluate the antiproliferative activity of BI-847325 on bladder cancer cells, showing high sensitivity PMC10599287
Acute myeloid leukemia cells 0.004-30 μmol/L 4 days Evaluate the inhibitory effect of PFK158 combined with meclizine on AML cells, showing synergistic inhibition PMC10599287
Acute lymphocytic leukemia cells 0.004-30 μmol/L 4 days Evaluate the antiproliferative activity of BI-847325 on acute lymphocytic leukemia cells, showing high sensitivity PMC10599287
A549 lung cancer cell line 30 μM 72 hours To evaluate the growth inhibitory effect of BI-847325 on A549 cells, showing a GI50 of 30 μM. PMC9283175
SW1736 1–64 μM 24–72 h Evaluate the cytotoxicity of BI-847325 in 3D culture system, showing an IC50 value of 34 μM PMC8641225
C643 1–64 μM 24–72 h Evaluate the cytotoxicity of BI-847325 in 3D culture system, showing an IC50 value of 15 μM PMC8641225
SW1736 0.125–8 μM 24–72 h Evaluate the inhibitory effect of BI-847325 on cell proliferation, showing an IC50 value of 4 μM PMC8641225
C643 0.125–8 μM 24–72 h Evaluate the inhibitory effect of BI-847325 on cell proliferation, showing an IC50 value of 2 μM PMC8641225

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB severe combined immune deficient (SCID) mice 1205Lu and 1205LuR xenograft models 70 mg/kg Oral gavage Once weekly for 65 days BI-847325 significantly suppressed the growth of BRAF-mutant and vemurafenib-resistant human melanoma xenografts. PMC4458462
Nude mice Subcutaneous xenograft models 40 and 80 mg/kg oral Once weekly for 3 or 4 weeks Evaluate the antitumor activity of BI-847325 in vivo in various cancer models, showing high activity in colorectal, gastric, mammary, and pancreatic cancer models PMC10599287

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.15mL

0.43mL

0.22mL

10.76mL

2.15mL

1.08mL

21.53mL

4.31mL

2.15mL

References

 

Historical Records

Categories